Earticle

초록

영어

Since the derivation of human embryonic stem cells, research in regenerative medicine has revolutionized our perspectives on the feasibility of cell-based therapies. We can hope for great advances in the treatment of major illnesses, ranging from diabetes to cardiac and neurological diseases. There is an increasing need for novel technologies to accelerate the development of stem cell science and therapeutic cell production. Cell population heterogeneity is a major obstacle to understanding and optimizing complex biological processes, such as when stem cell characteristics are obscured by average measurements of impure populations. In order to assess the heterogeneity within populations, we have developed microfluidic arrays with thousands of microbioreactors and analyzed single stem cells in nanoliter-scale clonal cultures. The differentiation of embryonic stem cells has led to the production of insulin-producing cells or their progenitors for the cellular therapy of diabetes. There is a renewed need for immobilized cell bioreactor innovation. We have developed bioreactors and processes suitable for producing therapeutic cells derived from embryonic stem cells up to ~1,000 L scales.

저자

• James M. PIRET [ Michael Smith Laboratories, Department of Chemical &Biological Engineering, University of British Columbia, Vancouver, Canada. ]

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국생물공학회 학술대회

• 간기

  반년간

• 수록기간

  1985~2013

• 십진분류

  KDC 476 DDC 576